CDC NEWS


powered by Surfing Waves


Latest News


What You Need to Know about Variants


27 Nov 2021

Omicron Variant No cases of this variant have been identified in the U.S. to date. CDC is following the details of this new variant. See CDC’s Media Statement.


Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters


19 Nov 2021

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices will meet later today to discuss further clinical recommendations.


Moderna COVID-19 booster may protect against variants


03 Nov 2021

At a Glance A booster of the Moderna COVID-19 vaccine increased levels of neutralizing antibodies against all variants of concern in a primate study. The findings suggest that COVID-19 boosters not only lengthen immunity but help broaden and strengthen the immune response.


DC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years


02 Nov 2021

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine. CDC now expands vaccine recommendations to about 28 million children in the United States in this age group and allows providers to begin vaccinating them as soon as possible.


Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows


26 Oct 2021

To see how COVID-19 vaccines are working in the real world, Israel has provided particularly compelling data. The fact that Israel is relatively small, keeps comprehensive medical records, and has a high vaccination rate with a single vaccine (Pfizer) has contributed to its robust data collection. Now, a new Israeli study offers some insight into those relatively uncommon breakthrough infections. It confirms that breakthrough cases, as might be expected, arise most often in individuals with lower levels of neutralizing antibodies.




Articles


How the Novavax Vaccine Works


03 Feb 2021

The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called NVX-CoV2373. The vaccine produced strikingly high levels of antibodies in early clinical trials.




Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic


19 Jan 2021

Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), the cause of coronavirus disease 2019 (COVID- 19), is a transmissible virus that infects the upper and lower respiratory tract, leading to a high viral titer in saliva and respiratory secretions.




COVID-19 as the Leading Cause of Death in the United States


12 Jan 2021

The current exponential increase in coronavirus dis- ease 2019 (COVID-19) is reaching a calamitous scale in the United States, potentially overwhelming the health care system and causing substantial loss of life.




Feds Authorize $22 Billion to Boost Vaccine Rollout


11 Jan 2021

The CDC will send $3 billion to the states to boost a lagging national COVID-19 vaccination program.




COVID-19 Immunity Could Last Longer Than 8 Months, Study Says


08 Jan 2021

Certain antibodies and memory cells likely last more than 8 months after someone has contracted the coronavirus, especially if they have a strong immune response to COVID-19, according to a new study published Wednesday in Science.




Enroll for Free